We present the case of a 55 year old who presented multiple times with altered conscious levels. He was often treated as being post-ictal, when in fact, he had Sodium Valproate induced hyperammonaemic encephalopathy. Sodium Valproate can frequently increase ammonia levels, and in some patient lead to hyperammonaemic encephalopathy.

References

1. Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RH, Hoffmann S. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J ClinPharmacol. 1986 Jul;22(1):100-3. PMID: 3091053;PMCID: PMC1401093
2. Chicharro AV, de Marinis AJ, Kanner AM. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy Behav. 2007 Nov;11(3):361-6. doi: 10.1016/j.yebeh.2007.06.015. Epub 2007 Sep 12. PMID: 17845866.
3. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007 Sep-Oct;20(5):499-502. doi: 10.3122/jabfm.2007.05.070062.PMID: 17823470.
4. Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M. Valproateinduced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia. 2002 Sep;43(9):1101-5. doi:10.1046/j.1528-1157.2002.42201.x. PMID: 12199737.
5. Grubben B, De Jonghe P, Cras P, Demey H, E, Parizel P, M:Valproate-Induced Hyperammonemic Encephalopathy: Imaging Findings on Diffusion-Weighted MRI. EurNeurol 2004;52:178-doi: 10.1159/000081861
6. Bolaños JP, Medina JM.Effect of valproate on the metabolism of the central nervous system. Life Sci. 1997;60(22):1933-42. doi:10.1016/s0024-3205(96)00687-x. PMID: 9180347
7. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-94. doi: 10.2165/00023210-200216100-00003.PMID: 12269861.
8. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003 Summer;9(2):199-216. doi: 10.1111/j.1527-3458.2003.tb00249.x. PMID: 12847559; PMCID:PMC6741662.
9. Romoli M, Mazzocchetti P, D’Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. CurrNeuropharmacol. 2019;17(10):926-946. doi: 10.2174/1570159X1766618122716572 PMID: 30592252; PMCID: PMC7052829.
10. Vázquez M, Fagiolino P, Maldonado C, Olmos I, Ibarra M, Alvariza S, Guevara N, Magallanes L, Olano I. Hyperammonemia associated with valproic acid concentrations. Biomed Res Int. 2014;2014:217269. doi: 10.1155/2014/217269. Epub 2014 Apr 29. PMID: 24868521; PMCID: PMC4020540.
11. Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care. 2005 Oct 5;9(5):431-40. doi: 10.1186/cc3742. Epub 2005 Jun 10. PMID: 16277730; PMCID: PMC1297603.
12. Durazzo A, Lucarini M, Nazhand A, et al. The Nutraceutical Value of Carnitine and Its Use in Dietary Supplements. Molecules. 2020;25(9):2127. Published 2020 May 1. doi:10.3390/molecules25092127
13. Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, Wanders RJ, Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008 Apr;31(2):205-16. doi: 10.1007/s10545-008-0841-x. Epub 2008 Apr 4. PMID: 18392741.
14. Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC. Risk factors of hyperammonemia in patients with epilepsy under valproic
    acid therapy. Medicine (Baltimore). 2014 Sep;93(11):e66. doi:10.1097/MD.0000000000000066. PMID: 25192484; PMCID:PMC4616274.
15. Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, Kagawa Y, Inoue Y. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012 Sep;101(3):202-9. doi: 10.1016/j.eplepsyres.2012.04.001. Epub 2012 Apr 28. PMID: 22542569.
16. Maldonado C, Guevara N, Silveira A, Fagiolino P, Vázquez M. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. J Int Med Res. 2017 Jun;45(3):1268-1272. doi:10.1177/0300060517703278. Epub 2017 Apr 20. PMID:28425821; PMCID: MC5536406.
17. Aiyer R, Seide M, Stern RG.Valproic Acid Induced Hyperammonemia in a Long Time Treated Patient. Case Rep Psychiatry. 2016;2016:6242314. doi: 10.1155/2016/6242314. Epub 2016 Jul 19. PMID: 27516916; PMCID: PMC4969522.
18. Machado MC, Pinheiro da Silva F. Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the intensive care setting. J Intensive Care. 2014 Mar 13;2(1):22. doi: 10.1186/2052-0492-2-22. PMID: 25908985; PMCID: PMC4407289.
19. Camilleri L. Lesson of the month 1: Sodium valproate-induced encephalopathy. Clin Med (Lond). 2018 Oct;18(5):430-432. doi:10.7861/clinmedicine.18-5-430. PMID: 30287443; PMCID:PMC6334110.
20. Raja, M. and Azzoni, A. (2002) Valproate-Induced Hyperammonaemia. Journal of Clinical Psychopharmacology, 22, 631-633.